FSWA
LGND icon

Financial Synergies Wealth Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Financial Synergies Wealth Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13
Closed -$951 – 278
2024
Q1 		$951 Buy
+13
New +$958 ﹤0.01% 414

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Financial Synergies Wealth Advisors's LGND Position: Q2 2024 in Review

Financial Synergies Wealth Advisors sold out of Ligand Pharmaceuticals (LGND) in Q2 2024, closing a stake of 13 shares — an estimated $951 sold.

Financial Synergies Wealth Advisors first reported a position in LGND in Q1 2024 and held it in 1 quarter. The position peaked at $951 in Q1 2024. 234 funds tracked by Wall St. Rank hold LGND as of Q2 2024.

  • Financial Synergies Wealth Advisors reported no remaining Ligand Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Financial Synergies Wealth Advisors sold 13 Ligand Pharmaceuticals shares in Q2 2024, an estimated $951.
  • Financial Synergies Wealth Advisors first reported a position in Ligand Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Financial Synergies Wealth Advisors's Ligand Pharmaceuticals position peaked at $951 in Q1 2024.
  • 234 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.

Based on Financial Synergies Wealth Advisors's 13F filing for Q2 2024, filed 23 Jul 2024.